Prevalence of Diagnosed Essential Tremor in the United States: An Administrative Claims-Based Study
Junji Lin, Rajesh Pahwa, Elan D. Louis, Ragy Saad, Kelly E. Lyons, Michael Markowitz, Liza R. Gibbs, Aisara Chansakul, John Kroner, Douglas S. Fuller, Weiyi Ni, Arthur Sillah, Michelle Baladi, Luigi M. Barbato, Sanket Shah

TL;DR
This study estimates that about 1.1 million US adults were diagnosed with essential tremor in 2024, highlighting the importance of case definitions and standardization in prevalence studies.
Contribution
The study provides updated age-standardized prevalence estimates of diagnosed essential tremor in the US using administrative claims data.
Findings
The age-standardized prevalence of diagnosed essential tremor was 0.42%, affecting an estimated 1.1 million US adults in 2024.
Prevalence increased with age, ranging from 0.06% in adults aged 18–40 to 1.61% in those aged ≥75.
Approximately 74% of diagnosed essential tremor patients received possible treatment.
Abstract
Essential tremor (ET) is one of the most common movement disorders. Previous estimates of ET prevalence vary due to multiple factors. This study estimated the prevalence of diagnosed ET. The prevalence of diagnosed ET was estimated among adults with continuous enrollment in 2022 and ≥1 additional year of prior baseline enrollment in the Merative™ MarketScan® Research Databases, a US administrative claims database. ET was defined as ≥2 ET claims within 12 months of one another during the 2016–2022 study period. The proportion of patients receiving treatment was defined as having a claim for possible medication for ET in 2022 among those with diagnosed ET who had an additional 6 months of follow-up following the first ET diagnosis claim. Age-standardized estimates of the number of US adults with diagnosed ET were calculated using 2024 US population census projections. The prevalence of…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsNeurological disorders and treatments · Glycogen Storage Diseases and Myoclonus · Genetic Neurodegenerative Diseases
